<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04705688</url>
  </required_header>
  <id_info>
    <org_study_id>RDC-2020.02</org_study_id>
    <nct_id>NCT04705688</nct_id>
  </id_info>
  <brief_title>Platelet-activation and Optimal Inhibition in Patients With Atrial Fibrillation Undergoing Left Atrial Appendage Occlusion</brief_title>
  <acronym>POPULAR-LAAO</acronym>
  <official_title>Platelet-activation and Optimal Inhibition in Patients With Atrial Fibrillation Undergoing Left Atrial Appendage Occlusion; The POPULAR-LAAO Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>R&amp;D Cardiologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>R&amp;D Cardiologie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The POPULAR-LAAO registry is an open-label observational prospective registry to investigate&#xD;
      hemostatic processes following left atrial appendage occlusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label observational prospective registry. The aim is to develop a better&#xD;
      understanding of coagulation, platelet reactivity and prothrombotic factors in the first&#xD;
      months after left atrial appendage occlusion, as occurrence of device-related thrombus and&#xD;
      optimal postprocedural management remain a challenge after LAAO.&#xD;
&#xD;
      The study population will consist of patients with non-valvular atrial fibrillation (AF) at&#xD;
      risk for cardio-embolic stroke scheduled for left atrial appendage occlusion. In these&#xD;
      patients, blood samples for coagulation and platelet reactivity testing will be taken, which&#xD;
      will be gathered prior to the procedure and 1 day, 14 days, 3 months and 6 months after the&#xD;
      procedure. Data will be analyzed longitudinally and between groups based on patient&#xD;
      characteristics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Change in coagulation activation</measure>
    <time_frame>Pre-LAAO and post-LAAO (1 day, 2 weeks, 3 months, 6 months)</time_frame>
    <description>Influence of LAAO on coagulation activation over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in platelet reactivity</measure>
    <time_frame>Pre-LAAO and post-LAAO (1 day, 2 weeks, 3 months, 6 months)</time_frame>
    <description>Influence of LAAO on platelet reactivity over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CYP2C19 genotype</measure>
    <time_frame>Pre-LAAO</time_frame>
    <description>Rate of clopidogrel non-responders among LAAO patients will be assessed by determining CYP2C19 genotype</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Separate and composite event rates of stroke (ischemic or hemorrhagic), transient ischemic attack (TIA), systemic embolism and cardiovascular death.</measure>
    <time_frame>Post-LAAO (3 months, 6 months, 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major and minor bleeding event rate (according to Bleeding Academic Research Consortium criteria)</measure>
    <time_frame>Post-LAAO (3 months, 6 months, 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device related thrombus event rate</measure>
    <time_frame>Post-LAAO (3 months, 12 months)</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Left Atrial Appendage Occlusion</arm_group_label>
    <description>Patients undergoing left atrial appendage occlusion.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples will be preserved for analysis of hemostatic markers and CYP2C19 genotyping.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of patients with non-valvular AF at high risk for&#xD;
        cardio-embolic stroke scheduled for left atrial appendage occlusion.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject is aged 18 years or older&#xD;
&#xD;
          -  The subject is accepted/scheduled for left atrial appendage occlusion&#xD;
&#xD;
          -  The subject has a CHA₂DS₂-VASc Score ≥2 (male) or ≥3 (female)&#xD;
&#xD;
          -  The subject or legal representative is able to understand and is willing to provide&#xD;
             written informed consent to participate in the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable or unwilling to return for required follow-up visits and examinations&#xD;
&#xD;
          -  Mechanical heart valves or valvular disease requiring surgery or interventional&#xD;
             procedure&#xD;
&#xD;
          -  Ongoing major bleeding or complicated or recent (&lt;72hours) major surgery&#xD;
&#xD;
          -  Known large oesophageal varices or decompensated liver disease (unless a documented&#xD;
             positive opinion of a gastro-enterologist)&#xD;
&#xD;
          -  Severe thrombocytopenia (&lt;50,000/ml)&#xD;
&#xD;
          -  High likelihood of being unavailable for follow-up or psycho-social condition making&#xD;
             study participation impractical.&#xD;
&#xD;
          -  Woman with child bearing potential who do not use an efficient method of&#xD;
             contraception.&#xD;
&#xD;
          -  Positive serum or urine pregnancy test for woman with child bearing potential&#xD;
&#xD;
          -  Pregnancy or within 48 hours post-partum&#xD;
&#xD;
          -  unsuitable LAA anatomy for occlusion or thrombus in the LAA at the time of procedure&#xD;
&#xD;
          -  contraindications or unfavourable conditions to perform cardiac catheterization or&#xD;
             transesophageal echocardiography (TEE)&#xD;
&#xD;
          -  atrial septal malformations, atrial septal defect or a high-risk patent foramen ovale&#xD;
             that may cause thrombo-embolic events&#xD;
&#xD;
          -  atrial septal defect repair or closure device or a patent foramen ovale repair or any&#xD;
             other anatomical condition as this may preclude an LAAO procedure&#xD;
&#xD;
          -  Mitral valve regurgitation grade 3 or more&#xD;
&#xD;
          -  Aortic valve stenosis (AVA&lt;1.0 cm2 or Pmax&gt;50 mmHg) or regurgitation grade 3 or more&#xD;
&#xD;
          -  Planned carotid endarterectomy (CEA) for significant carotid artery disease&#xD;
&#xD;
          -  Life expectancy of less than 1 year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucas VA Boersma, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ST. Antonius hospital Nieuwegein</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucas VA Boersma, MD PhD</last_name>
    <phone>+31 088 320 3000</phone>
    <email>l.boersma@antoniusziekenhuis.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Errol W Aarnink, MD</last_name>
    <phone>+31 088 320 3000</phone>
    <email>e.aarnink@antoniusziekenhuis.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <zip>3430 EM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L.V.A. Boersma, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>L.V.A. Boersma, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>E.W. Aarnink, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>R&amp;D Cardiologie</investigator_affiliation>
    <investigator_full_name>L.V.A. Boersma</investigator_full_name>
    <investigator_title>Clinical professor</investigator_title>
  </responsible_party>
  <keyword>Left atrial appendage occlusion</keyword>
  <keyword>Device-related thrombus</keyword>
  <keyword>Platelet reactivity</keyword>
  <keyword>Coagulation activation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

